List of therapeutic monoclonal antibodies

Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

mab: whole monoclonal antibody
Fab: fragment, antigen-binding (one arm)
- F(ab')₂: fragment, antigen-binding, including hinge region (both arms)
- Fab': fragment, antigen-binding, including hinge region (one arm)
Variable fragments:
- scFv: single-chain variable fragment
- di-scFv: dimeric single-chain variable fragment
- sdAb: single-domain antibody
BsAb: bispecific monoclonal antibody:
- 3funct: trifunctional antibody
- BiTE: bi-specific T-cell engager

This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

Name	Brand name	Type	Source	Target	Approved	Use
3F8		mab	mouse	GD2 ganglioside		neuroblastoma
Abagovomab[1]		mab	mouse	CA-125 (imitation)		ovarian cancer
Abciximab[2]	ReoPro	Fab	chimeric	CD41 (integrin alpha-IIb)	Y[3]	platelet aggregation inhibitor
Abituzumab[4]		mab	humanized	CD51		cancer
Abrezekimab[5]		Fab	humanized	IL-13
Abrilumab[6]		mab	human	integrin α₄ β₇		inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab[6]		mab	human	Clostridium difficile		Clostridium difficile colitis
Adalimumab[7]	Humira	mab	human	TNF-α	Y[8]	rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn
Adecatumumab[9]		mab	human	EpCAM		prostate and breast cancer
Aducanumab[10]	Aduhelm	mab	human	Amyloid beta	Y[11]	Alzheimer's disease
Afasevikumab[12]		mab	human	IL-17A, IL-17F		multiple sclerosis
Afelimomab[2]		F(ab')₂	mouse	TNF-α		sepsis
Alacizumab pegol[13]		F(ab')₂	humanized	VEGFR2		cancer
Alemtuzumab[14]	Lemtrada, Campath	mab	humanized	CD52	Y	multiple sclerosis
Alirocumab[15]	Praluent	mab	human	PCSK9	Y	hypercholesterolemia
Altumomab pentetate	Hybri-ceaker	mab	mouse	Carcinoembryonic antigen (CEA)		colorectal cancer (diagnosis)
Amatuximab[16]		mab	chimeric	mesothelin		cancer
Amivantamab	Rybrevant	BsAb	human	Epidermal growth factor receptor (EGFR), cMet	Y	non-small cell lung cancer
Anatumomab mafenatox[17]		Fab	mouse	Tumor-associated glycoprotein 72 (TAG-72)		non-small cell lung cancer
Andecaliximab[18]		mab	chimeric	gelatinase B		gastric cancer or gastroesophageal junction adenocarcinoma
Anetumab ravtansine[4]		mab	human	mesothelin (MSLN)		cancer
Anifrolumab[4]	Saphnelo	mab	human	IFN-α/β receptor	Y[19]	systemic lupus erythematosus
Ansuvimab	Ebanga	mab	human	Ebola virus glycoprotein	Y	treatment of Zaire ebolavirus (Ebola virus)
Anrukinzumab[13] (= IMA-638)[20]		mab	humanized	IL-13		asthma
Apolizumab[21]		mab	humanized	HLA-DR		hematological cancers
Aprutumab ixadotin[22]		mab	human	FGFR2
Arcitumomab[23]	CEA-Scan	Fab'	mouse	Carcinoembryonic antigen (CEA)		gastrointestinal cancers (diagnosis)
Ascrinvacumab[12]		mab	human	activin receptor-like kinase 1		cancer
Aselizumab[24]		mab	humanized	L-selectin (CD62L)		severely injured patients
Atezolizumab[25]	Tecentriq	mab	humanized	PD-L1	Y	cancer
Atidortoxumab[26]		mab	human	Staphylococcus aureus alpha toxin
Atinumab[16]		mab	human	RTN4
Atoltivimab		mab	human			part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Atoltivimab/maftivimab/odesivimab	Inmazeb	mab	human		Y	treatment of Zaire ebolavirus (Ebola virus)
Atorolimumab[2]		mab	human	Rhesus factor		hemolytic disease of the newborn
Avelumab[12]	Bavencio	mab	human	PD-L1	Y	cancer
Azintuxizumab vedotin[27]		mab	chimeric/ humanized	CD319		cancer
Bamlanivimab[28]		mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Emergency Use Authorization (EUA) when used with etesevimab[29]	COVID-19
Bapineuzumab[30]		mab	humanized	β-amyloid		Alzheimer's disease
Basiliximab[31]	Simulect	mab	chimeric	CD25 (α chain of IL-2 receptor)	Y	prevention of organ transplant rejections
Bavituximab[1]		mab	chimeric	phosphatidylserine		cancer, viral infections
BCD-100			human	PD-1		melanoma
Bebtelovimab[32]		mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Emergency Use Authorization (EUA)[33]	COVID-19
Bectumomab[31]	LymphoScan	Fab'	mouse	CD22		non-Hodgkin's lymphoma (detection)
Bedinvetmab[34]	Librela[35]	mab	veterinary	nerve growth factor (NGF)[35]	Y	pain associated with osteoarthritis in dogs[35]
Begelomab[6]		mab	mouse	DPP4
Belantamab mafodotin[5]	Blenrep	mab	humanized	B-cell maturation antigen (BCMA)	Y	relapsed or refractory multiple myeloma
Belimumab[36]	Benlysta	mab	human	B-cell activating factor (BAFF)	Y	systemic lupus erythematosus without renal or CNS involvement
Bemarituzumab[26]		mab	humanized	FGFR2		gastric cancer or gastroesophageal junction adenocarcinoma
Benralizumab[37]	Fasenra	mab	humanized	CD125	Y	asthma
Berlimatoxumab[26]		mab	human	Staphylococcus aureus bi-component leukocidin
Bermekimab[31]	Xilonix	mab	human	IL-1α		colorectal cancer
Bersanlimab[5]		mab	human	ICAM-1
Bertilimumab[24]		mab	human	CCL11 (eotaxin-1)		severe allergic disorders
Besilesomab[38]	Scintimun	mab	mouse	Carcinoembryonic antigen (CEA)-related antigen		inflammatory lesions and metastases (detection)
Bevacizumab[14]	Avastin	mab	humanized	VEGF-A	Y	metastatic cancer, retinopathy of prematurity
Bezlotoxumab[31]	Zinplava	mab	human	Clostridium difficile	Y	Clostridium difficile colitis
Biciromab[31]	FibriScint	Fab'	mouse	fibrin II, beta chain		thromboembolism (diagnosis)
Bimagrumab[39]		mab	human	ACVR2B		myostatin inhibitor
Bimekizumab[10]	Bimzelx	mab	humanized	IL-17A, IL-17F, IL-17AF	Y	psoriasis
Birtamimab		mab	chimeric	serum amyloid A protein		amyloidosis
Bivatuzumab[31]		mab	humanized	CD44 v6		squamous cell carcinoma
Bleselumab[12]		mab	human	CD40		organ transplant rejection
Blinatumomab[31]	Blincyto	BiTE	mouse	CD19	Y	pre-B Acute lymphoblastic leukemia (ALL) (CD19+)
Blontuvetmab[40]	Blontress	mab	veterinary	CD20
Blosozumab[41]		mab	humanized	SOST		osteoporosis
Bococizumab[31]		mab	humanized	PCSK9		dyslipidemia
Brazikumab[18]		mab	human	IL-23		Crohn's disease
Brentuximab vedotin[31]	Adcentris	mab	chimeric	CD30 (TNFRSF8)	Y	Hodgkin's lymphoma, anaplastic large-cell lymphoma
Briakinumab[31]		mab	human	IL-12, IL-23		psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab[41]	Siliq	mab	human	IL-17	Y	Plaque psoriasis
Brolucizumab[25]	Beovu	scFv	humanized	vascular endothelial growth factor A (VEGFA)	Y	wet age-related macular degeneration
Brontictuzumab[6]		mab	humanized	Notch 1		cancer
Burosumab[18]	Crysvita	mab	human	FGF 23	Y	X-linked hypophosphatemia
Cabiralizumab[40]		mab	humanized	CSF1R		metastatic pancreatic cancer
Camidanlumab tesirine[26]		mab	human	CD25 (α chain of IL-2 receptor)		B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
Camrelizumab[22]		mab	humanized	PD-1		hepatocellular carcinoma
Canakinumab[42]	Ilaris	mab	human	IL-1	Y	cryopyrin-associated periodic syndrome
Cantuzumab mertansine[41]		mab	humanized	CanAg (a glycoform of MUC1)		colorectal cancer etc.
Cantuzumab ravtansine[41]		mab	humanized	CanAg (a glycoform of MUC1)		cancers
Caplacizumab[43]	Cablivi	sdAb	humanized	VWF	Y	thrombotic thrombocytopenic purpura, thrombosis
Casirivimab[28]		mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Yes when used with imdevimab[44][45]	COVID-19
Capromab[31]	Prostascint	mab	mouse	Glutamate carboxypeptidase II	Y	prostate cancer (detection)
Carlumab[16]		mab	human	MCP-1		oncology/immune indications
Carotuximab[40]		mab	chimeric	endoglin		angiosarcoma
Catumaxomab[30]	Removab	3funct	rat/mouse hybrid	EpCAM, CD3	Y	ovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugate		mab	humanized	Lewis-Y antigen		cancer
Cedelizumab[46]		mab	humanized	CD4		prevention of organ transplant rejections, treatment of autoimmune diseases
Cemiplimab[31]	Libtayo	mab	human	PD-1	Y	cutaneous squamous cell carcinoma
Cergutuzumab amunaleukin[12]		mab	humanized	IL-2		cancer
Certolizumab pegol[42]	Cimzia	Fab'	humanized	TNF-α	Y	Crohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis
Cetrelimab[5]		mab	human	PD-1		cancer
Cetuximab[31]	Erbitux	mab	chimeric	Epidermal growth factor receptor (EGFR)	Y	metastatic colorectal cancer and head and neck cancer
Cibisatamab[5]		mab	humanized	CEACAM5		cancer
Cilgavimab[28]		mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Emergency Use Authorization (EUA) when used with tixagevimab[47]	COVID-19
Cirmtuzumab[31]			humanized	ROR1		chronic lymphocytic leukemia
Citatuzumab bogatox[48]		Fab	humanized	EpCAM		ovarian cancer and other solid tumors
Cixutumumab[31]		mab	human	IGF-1 receptor (CD221)		solid tumors
Clazakizumab[49]		mab	humanized	IL-6		rheumatoid arthritis
Clenoliximab[31]		mab	chimeric	CD4		rheumatoid arthritis
Clivatuzumab tetraxetan[31]	hPAM4-Cide	mab	humanized	MUC1		pancreatic cancer
Codrituzumab[4]		mab	humanized	glypican 3		cancer
Cofetuzumab pelidotin[26]		mab	humanized	PTK7		cancer
Coltuximab ravtansine[4]		mab	chimeric	CD19		cancer
Conatumumab[48]		mab	human	TRAIL-R2		cancer
Concizumab[50]	Alhemo	mab	humanized	tissue factor pathway inhibitor (TFPI)	Y	bleeding with hemophilia
Cosfroviximab[27]	ZMapp	mab	chimeric	ebolavirus glycoprotein		Ebola virus
Crenezumab[31]		mab	humanized	β-amyloid (1-40 and 1-42)		Alzheimer's disease
Crizanlizumab[22]	Adakveo	mab	humanized	selectin P	Y	sickle-cell disease
Crotedumab[40]		mab	human	glucagon receptor (GCGR)		diabetes
CR6261		mab	human	Hemagglutinin (influenza)		infectious disease/influenza A
Cusatuzumab[5]		mab	humanized	CD70		cancer
Dacetuzumab[13]		mab	humanized	CD40		hematologic cancers
Daclizumab[51]	Zenapax	mab	humanized	CD25 (α chain of IL-2 receptor)	Y	prevention of organ transplant rejections, multiple sclerosis
Dalotuzumab		mab	humanized	IGF-1 receptor (CD221)		cancer etc.
Dapirolizumab pegol[52]		mab	humanized	CD154 (CD40L)
Daratumumab[53]	Darzalex	mab	human	CD38	Y[54]	multiple myeloma
Dectrekumab[25]		mab	human	IL-13
Demcizumab		mab	humanized	DLL4		cancer
Denintuzumab mafodotin[6]		mab	humanized	CD19		cancer
Denosumab[55]	Prolia	mab	human	RANKL	Y	osteoporosis, bone metastases etc.
Depatuxizumab mafodotin[22]		mab	chimeric/ humanized	EGFR		glioblastoma
Derlotuximab biotin		mab	chimeric	histone complex		recurrent glioblastoma multiforme
Detumomab		mab	mouse	B-lymphoma cell		lymphoma
Dezamizumab[22]		mab	humanized	serum amyloid P component
Dinutuximab	Unituxin	mab	chimeric	GD2 ganglioside	Y	neuroblastoma
Dinutuximab beta	Qarziba	mab	chimeric	GD2 ganglioside	Y	neuroblastoma
Diridavumab		mab	human	Hemagglutinin (influenza)		influenza A
Domagrozumab[40]		mab	humanized	GDF-8		Duchenne muscular dystrophy
Donanemab		mab	humanized	Amyloid beta		Alzheimer's disease
Dorlimomab aritox[56]		F(ab')₂	mouse
Dostarlimab[57]	Jemperli	mab	humanized	PCDP1	Y	endometrial cancer
Drozitumab		mab	human	DR5		cancer etc.
DS-8201			humanized	HER2		gastric or gastroesophageal junction adenocarcinoma
Duligotuzumab[15]		mab	humanized	ERBB3 (HER3)		testicular cancer
Dupilumab[39]	Dupixent	mab	human	IL-4Rα	Y	atopic dermatitis, asthma, nasal polyps
Durvalumab[25]	Imfinzi	mab	human	PD-L1	Y	cancer
Dusigitumab		mab	human	IGF-2		B-cell malignancies
Duvortuxizumab[27]		scFv	chimeric/ humanized	CD19, CD3E		cancer
Ecromeximab[21]		mab	chimeric	GD3 ganglioside		malignant melanoma
Eculizumab[21]	Soliris	mab	humanized	C5	Y	paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Edobacomab		mab	mouse	endotoxin		sepsis caused by Gram-negative bacteria
Edrecolomab	Panorex	mab	mouse	EpCAM		colorectal carcinoma
Efalizumab[7]	Raptiva	mab	humanized	LFA-1 (CD11a)		psoriasis (blocks T-cell migration)
Efungumab[1]	Mycograb	scFv	human	Hsp90		invasive Candida infection
Eldelumab[4]		mab	human	CXCL10 (IP-10)		Crohn's disease, ulcerative colitis
Elezanumab[22]		mab	human	repulsive guidance molecule A (RGMA)		spinal cord injury and multiple sclerosis
Elgemtumab[25]		mab	human	ERBB3 (HER3)		cancer
Elotuzumab	Empliciti	mab	humanized	SLAMF7	Y	multiple myeloma
Elsilimomab		mab	mouse	IL-6
Emactuzumab[6]		mab	humanized	CSF1R		cancer
Emapalumab[22]	Gamifant	mab	human	IFN-γ	Y	hemophagocytic lymphohistiocytosis
Emibetuzumab		mab	humanized	HGFR		cancer
Emicizumab[12]	Hemlibra	BsAb	humanized	activated F9, F10	Y	haemophilia A
Enapotamab vedotin[5]		mab	human	AXL		cancer
Enavatuzumab		mab	humanized	TWEAK receptor		cancer etc.
Enfortumab vedotin[4]	Padcev	mab	human	nectin-4	Y[58]	urothelial cancer
Enlimomab pegol[59]		mab	mouse	ICAM-1 (CD54)
Enoblituzumab[22]		mab	humanized	CD276		cancer
Enokizumab		mab	humanized	IL-9		asthma
Enoticumab[15]		mab	human	DLL4
Ensituximab		mab	chimeric	MUC5AC		cancer
Epcoritamab	Epkinly[60][61]	BiTE	humanized	CD3, CD20	Y	diffuse large B-cell lymphoma
Epitumomab cituxetan[62]		mab	mouse	episialin
Epratuzumab		mab	humanized	CD22		cancer, systemic lupus erythematosus (SLE)
Eptinezumab[22]	Vyepti	mab	humanized	calcitonin gene-related peptide	Y[63]	migraine
Erenumab[22]	Aimovig	mab	human	calcitonin gene-related peptide receptor (CGRP)	Y	migraine
Erlizumab[64]		F(ab')₂	humanized	ITGB2 (CD18)		heart attack, stroke, traumatic shock
Ertumaxomab[30]	Rexomun	3funct	rat/mouse hybrid	HER2/neu, CD3	Y	breast cancer etc.
Etaracizumab	Abegrin	mab	humanized	integrin α_vβ₃	Y	melanoma, prostate cancer, ovarian cancer etc.
Etesevimab[28]		mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Emergency Use Authorization (EUA) when used with bamlanivimab[29]	COVID-19
Etigilimab[5]		mab	humanized	TIGIT
Etrolizumab[16]		mab	humanized	integrin β₇		inflammatory bowel disease
Evinacumab	Evkeeza	mab	human	angiopoietin 3	Y	dyslipidemia
Evolocumab[39]	Repatha	mab	human	PCSK9	Y	hypercholesterolemia
Exbivirumab[65]		mab	human	hepatitis B surface antigen		hepatitis B
Fanolesomab[17]	NeutroSpec	mab	mouse	CD15		appendicitis (diagnosis)
Faralimomab		mab	mouse	IFN receptor
Faricimab[66]	Vabysmo	mab	humanized	VEGF-A and Ang-2	Y	angiogenesis, ocular vascular diseases
Farletuzumab		mab	humanized	folate receptor 1		ovarian cancer
Fasinumab		mab	human	nerve growth factor (NGF)		acute sciatic pain
FBTA05[67][68]	Lymphomun	3funct	rat/mouse hybrid	CD20		chronic lymphocytic leukaemia
Felvizumab		mab	humanized	respiratory syncytial virus		respiratory syncytial virus infection
Fezakinumab[69][70]		mab	human	IL-22		rheumatoid arthritis, psoriasis
Fibatuzumab[71]		mab	humanized	ephrin receptor A3
Ficlatuzumab		mab	humanized	Hepatocyte growth factor (HGF)		cancer etc.
Figitumumab		mab	human	IGF-1 receptor (CD221)		adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[6]		mab	human	Hemagglutinin (influenza)
Flanvotumab		mab	human	TYRP1 (glycoprotein 75)		melanoma
Fletikumab		mab	human	IL-20		rheumatoid arthritis
Flotetuzumab[5]		di-scFv	humanized	IL-3 receptor		hematological malignancies
Fontolizumab[21]	HuZAF	mab	humanized	IFN-γ		Crohn's disease etc.
Foralumab[72]		mab	human	CD3E
Foravirumab[48]		mab	human	rabies virus glycoprotein		rabies (prophylaxis)
Fremanezumab[22]	Ajovy	mab	humanized	calcitonin gene-related peptide alpha and beta	Y	migraine
Fresolimumab[53]		mab	human	TGF-β		idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Frovocimab[57]		mab	humanized	PCSK9		hypercholesterolemia
Frunevetmab[73]	Solensia[74]	mab	veterinary	nerve growth factor (NGF)[74]	Y	pain associated with osteoarthritis in cats[74]
Fulranumab		mab	human	nerve growth factor (NGF)		pain
Futuximab[15]		mab	chimeric	Epidermal growth factor receptor (EGFR)		cancer
Galcanezumab[40]	Emgality	mab	humanized	calcitonin	Y	migraine
Galiximab		mab	chimeric	CD80		B-cell lymphoma
Gancotamab		scFv	human	HER2/neu		cancer
Ganitumab		mab	human	IGF-1 receptor (CD221)		cancer
Gantenerumab[42]		mab	human	β-amyloid (1-40 and 1-42)		Alzheimer's disease
Gatipotuzumab[27]		mab	humanized	MUC1		cancer
Gavilimomab[64]		mab	mouse	CD147 (basigin)		graft versus host disease
Gedivumab[27]		mab	human	Hemagglutinin (influenza)
Gemtuzumab ozogamicin[22]	Mylotarg	mab	humanized	CD33	Y	acute myelogenous leukemia
Gevokizumab		mab	humanized	IL-1β		diabetes etc.
Gilvetmab[27]		mab	veterinary	PCDC1
Gimsilumab[26]		mab	human	CSF2		rheumatoid arthritis
Girentuximab[53]	Rencarex	mab	chimeric	carbonic anhydrase 9 (CA-IX)		clear cell renal cell carcinoma[75]
Glembatumumab vedotin[37][76]		mab	human	GPNMB		melanoma, breast cancer
Glofitamab[60]	Columvi[77]	BsAb	humanized	CD20, CD3	Y[77]	diffuse large B-cell lymphoma[77]
Golimumab[65]	Simponi	mab	human	TNF-α	Y	rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab		mab	chimeric	CD23 (IgE receptor)		allergic asthma
Gosuranemab		mab	humanized	tau protein		progressive supranuclear palsy
Guselkumab	Tremfya	mab	human	IL-23	Y	psoriasis
Ianalumab[26]		mab	human	BAFF-R		autoimmune hepatitis
Ibalizumab[42]	Trogarzo	mab	humanized	CD4	Y	HIV infection
Sintilimab			human	PD-1		squamous cell non-small cell lung cancer
Ibritumomab tiuxetan	Zevalin	mab	mouse	CD20	Y	non-Hodgkin's lymphoma
Icrucumab		mab	human	VEGFR-1		cancer etc.
Idarucizumab[4]	Praxbind	mab	humanized	dabigatran	Y	reversal of anticoagulant effects of dabigatran
Ifabotuzumab[22]		mab	humanized	EPHA3		glioblastoma multiforme[78]
Igovomab	Indimacis-125	F(ab')₂	mouse	CA-125		ovarian cancer (diagnosis)
Iladatuzumab vedotin[26]		mab	humanized	CD79B		cancer
Imalumab[6]		mab	human	macrophage migration inhibitory factor (MIF)		cancer
Imaprelimab[5]		mab	humanized	melanoma cell adhesion molecule (MCAM)
Imciromab	Myoscint	mab	mouse	cardiac myosin	Y	cardiac imaging
Imdevimab[28]		mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Yes when used with casirivimab[44][45]	COVID-19
Imgatuzumab[15]		mab	humanized	Epidermal growth factor receptor (EGFR)		cancer
Inclacumab[43]		mab	human	selectin P		cardiovascular disease
Indatuximab ravtansine[41]		mab	chimeric	SDC1		cancer
Indusatumab vedotin[25]		mab	human	GUCY2C		cancer
Inebilizumab[12]	Uplizna	mab	humanized	CD19	Y[79]	cancer, systemic sclerosis, multiple sclerosis
Infliximab	Remicade	mab	chimeric	TNF-α	Y	rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[80][81]		mab	human	CD51		solid tumors (prostate cancer, melanoma)
Inolimomab		mab	mouse	CD25 (α chain of IL-2 receptor)		graft versus host disease
Inotuzumab ozogamicin[38]	Besponsa	mab	humanized	CD22	Y	Acute lymphoblastic leukemia (ALL)
Ipilimumab[55]	Yervoy	mab	human	CD152	Y	melanoma
Iomab-B			mouse	CD45		ablation of bone marrow
Iratumumab[55]		mab	human	CD30 (TNFRSF8)		Hodgkin's lymphoma
Isatuximab	Sarclisa	mab	chimeric	CD38	Y	multiple myeloma
Iscalimab[5]		mab	human	CD40
Istiratumab[26]		mab	human	IGF-1 receptor (CD221)		advanced solid tumors
Itolizumab[72]	Alzumab	mab	humanized	CD6	Y	psoriasis
Ixekizumab	Taltz	mab	humanized	IL-17A	Y	autoimmune diseases
Keliximab		mab	chimeric	CD4		chronic asthma
Labetuzumab[7]	CEA-Cide	mab	humanized	Carcinoembryonic antigen (CEA)		colorectal cancer
Lacnotuzumab[27]		mab	humanized	CSF1, macrophage colony stimulating factor (MCSF)		cancer
Ladiratuzumab vedotin[26]		mab	humanized	LIV-1		cancer
Lampalizumab[15]		Fab	humanized	Complement factor D (CFD)		geographic atrophy secondary to age-related macular degeneration
Lanadelumab[40]	Takhzyro	mab	human	kallikrein	Y	angioedema
Landogrozumab[12]		mab	humanized	GDF-8		muscle wasting disorders
Laprituximab emtansine[40]		mab	chimeric	epidermal growth factor receptor (EGFR)
Larcaviximab[27]		mab	chimeric	ebolavirus glycoprotein		Ebola virus
Lebrikizumab		mab	humanized	IL-13		asthma
Lecanemab[82]	Leqembi	mab	humanized	β-amyloid	Y[83]	Alzheimer's disease
Lemalesomab[64]		mab	mouse	NCA-90 (granulocyte antigen)		diagnostic agent
Lendalizumab[40]		mab	humanized	C5
Lenvervimab[5]		mab	humanized	hepatitis B surfage antigen		hepatitis B
Lenzilumab[6]		mab	human	CSF2		chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia
Lerdelimumab[17]		mab	human	TGF-β2		reduction of scarring after glaucoma surgery
Leronlimab[5]		mab	humanized	CCR5		breast cancer, HIV
Lesofavumab[27]		mab	human	Hemagglutinin (influenza)
Letolizumab[27]		scFv	humanized	tumor necrosis factor related activation protein (TRAP)		inflammatory diseases
Lexatumumab[1]		mab	human	TRAIL-R2		cancer
Libivirumab[65]		mab	human	hepatitis B surface antigen		hepatitis B
Lifastuzumab vedotin		mab	humanized	phosphate-sodium co-transporter		cancer
Ligelizumab[15]		mab	humanized	IGHE		severe asthma, chronic spontaneous urticaria
Loncastuximab tesirine[84][71]	Zynlonta	mab	chimeric	CD19	Y	relapsed or refractory large B-cell lymphoma
Losatuxizumab vedotin[27]		mab	chimeric/ humanized	epidermal growth receptor factor (EGRF), ERBB1 HER1		cancer
Lilotomab satetraxetan[25]		mab	mouse	CD37		cancer
Lintuzumab		mab	humanized	CD33		cancer
Lirilumab[15]		mab	human	KIR2D		solid and hematological cancers
Lodelcizumab[39]		mab	humanized	PCSK9		hypercholesterolemia
Lokivetmab[25]	Cytopoint[85]	mab	veterinary	Canis lupus familiaris IL31	Y	clinical signs of atopic dermatitis in dogs[85]
Lorvotuzumab mertansine		mab	humanized	CD56		cancer
Lucatumumab[13]		mab	human	CD40		multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol[6]		mab	humanized	CD28		autoimmune diseases
Lumiliximab[9]		mab	chimeric	CD23 (IgE receptor)		chronic lymphocytic leukemia
Lumretuzumab[6]		mab	humanized	ERBB3 (HER3)		cancer
Lupartumab[22]		mab	human
Lupartumab amadotin[22]		mab	human	LYPD3
Lutikizumab[22]		mab	humanized	IL-1α
Maftivimab		mab	human			part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Mapatumumab[30]		mab	human	TRAIL-R1		cancer
Margetuximab	Margenza[86]	mab	humanized	HER2	Y	breast cancer
Marstacimab		mab	human	tissue factor pathway inhibitor (TFPI)		bleeding with hemophilia
Maslimomab			mouse	T-cell receptor
Mavrilimumab[37]		mab	human	GMCSF receptor α-chain		rheumatoid arthritis
Matuzumab[24]		mab	humanized	Epidermal growth factor receptor (EGFR)		colorectal, lung and stomach cancer
Mepolizumab[46]	Bosatria	mab	humanized	IL-5	Y	asthma and white blood cell diseases
Metelimumab[24]		mab	human	TGF-β1		systemic scleroderma
Milatuzumab[13]		mab	humanized	CD74		multiple myeloma and other hematological malignancies
Minretumomab		mab	mouse	TAG-72		tumor detection (and therapy?)
Mirikizumab[84]	Omvoh	mab	humanized	IL-23	Y	ulcerative colitis
Mirvetuximab soravtansine[12]	Elahere	mab	chimeric	folate receptor alpha	Y[87]	ovarian cancer
Mitumomab		mab	mouse	GD3 ganglioside		small cell lung carcinoma
Modotuximab		mab	chimeric	EGFR extracellular domain III		cancer
Mogamulizumab[16]	Poteligeo	mab	humanized	CCR4	Y	adult T-cell leukemia/lymphoma
Monalizumab[12]		mab	humanized	NKG2A		rheumatoid arthritis, gynecologic malignancies, and other cancers
Morolimumab[88]		mab	human	Rhesus factor
Mosunetuzumab[84]	Lunsumio	BiTE	humanized	CD3E, MS4A1, CD20	Y[89]	follicular lymphoma
Motavizumab[1]	Numax	mab	humanized	respiratory syncytial virus		respiratory syncytial virus (prevention)
Moxetumomab pasudotox	Lumoxiti	mab	mouse	CD22	Y	hairy cell leukemia
Muromonab-CD3[90][91]	Orthoclone OKT3	mab	mouse	CD3		prevention of organ transplant rejections
Nacolomab tafenatox		Fab	mouse	C242 antigen		colorectal cancer
Namilumab[16]		mab	human	CSF2
Naptumomab estafenatox[92]		Fab	mouse	5T4		non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine[40]		mab	chimeric	CD37
Narnatumab		mab	human	MST1R (aka RON)		cancer
Natalizumab[88]	Tysabri	mab	humanized	integrin α₄	Y	multiple sclerosis, Crohn's disease
Navicixizumab[40]		mab	chimeric/ humanized	DLL4 and VEGFA		cancer
Navivumab[12]		mab	human	Hemagglutinin (influenza)
Naxitamab	Danyelza		humanized	c-Met	Y	high-risk neuroblastoma and refractory osteomedullary disease
Nebacumab		mab	human	endotoxin		sepsis
Necitumumab[93]	Portrazza	mab	human	Epidermal growth factor receptor (EGFR)	Y	non-small cell lung carcinoma
Nemolizumab[25]		mab	humanized	IL-31 receptor A		eczema[94]
NEOD001			humanized	amyloid		primary systemic amyloidosis
Nerelimomab		mab	mouse	TNF-α
Nesvacumab		mab	human	angiopoietin 2		cancer
Netakimab[5]	Efleira	mab	chimeric	IL-17A		plaque psoriasis
Nimotuzumab[55][95]	BioMab-EGFR, Theracim, Theraloc	mab	humanized	epidermal growth factor receptor (EGFR)	Y	squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nirsevimab		mab	human	RSV fusion glycoprotein		respiratory syncytial virus
Nivolumab[6]	Opdivo	mab	human	PD-1	Y	cancer
Nofetumomab merpentan	Verluma	Fab	mouse			cancer (diagnosis)
Obiltoxaximab	Anthim	mab	chimeric	Bacillus anthracis anthrax	Y	Bacillus anthracis spores
Obinutuzumab	Gazyva	mab	humanized	CD20	Y	chronic lymphatic leukemia
Ocaratuzumab		mab	humanized	CD20		cancer
Ocrelizumab[96]	Ocrevus	mab	humanized	CD20	Y	multiple sclerosis
Odesivimab		mab	human			part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Odulimomab		mab	mouse	LFA-1 (CD11a)		prevention of organ transplant rejections, immunological diseases
Ofatumumab[30]	Arzerra, Kesimpta[97]	mab	human	CD20	Y	chronic lymphocytic leukemia, multiple sclerosis[97]
Olaratumab	Lartruvo	mab	human	PDGFRA	Y	cancer
Oleclumab[27]		mab	human	5'-nucleotidase		pancreatic and colorectal cancer
Olendalizumab[27]		mab	humanized	complement C5a		systemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease
Olokizumab[72]		mab	humanized	IL-6		rheumatoid arthritis
Omalizumab[64]	Xolair	mab	humanized	IgE Fc region	Y	allergic asthma, chronic spontaneous urticaria
Omburtamab[57]		mab	mouse	CD276		cancer
OMS721			human	MASP-2		atypical hemolytic uremic syndrome
Onartuzumab		Fab	humanized	human scatter factor receptor kinase		cancer
Ontuxizumab		mab	chimeric/ humanized	TEM1		cancer
Onvatilimab[5]		mab	human	VISTA (protein) (VSIR)
Opicinumab		mab	human	LINGO-1		multiple sclerosis
Oportuzumab monatox[93]	Vicinium	scFv	humanized	EpCAM		bladder cancer
Oregovomab[17]	OvaRex	mab	mouse	CA-125		ovarian cancer
Orticumab[15]		mab	human	oxLDL
Otelixizumab[13]		mab	chimeric/ humanized	CD3		diabetes mellitus type 1
Otilimab		mab	human	GMCSF		osteoarthritis, rheumatoid arthritis
Otlertuzumab		mab	humanized	CD37		cancer
Oxelumab[41]		mab	human	OX-40		asthma
Ozanezumab		mab	humanized	NOGO-A		ALS and multiple sclerosis
Ozoralizumab[41]		mab	humanized	TNF-α		inflammation
Pagibaximab[30]		mab	chimeric	lipoteichoic acid		sepsis (Staphylococcus)
Palivizumab	Synagis, Abbosynagis	mab	humanized	F protein of respiratory syncytial virus	Y	respiratory syncytial virus (prevention)
Pamrevlumab[12]		mab	human	connective tissue growth factor (CTGF)		idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab[65]	Vectibix	mab	human	epidermal growth factor receptor (EGFR)	Y	colorectal cancer
Pankomab		mab	humanized	tumor specific glycosylation of MUC1		ovarian cancer
Panobacumab[93]		mab	human	Pseudomonas aeruginosa		Pseudomonas aeruginosa infection
Parsatuzumab[15]		mab	humanized	EGFL7		cancer
Pascolizumab[21]		mab	humanized	IL-4		asthma
Pasotuxizumab[6]		mab	chimeric/ humanized	folate hydrolase		cancer
Pateclizumab[41]		mab	humanized	lymphotoxin alpha (LTA)		TNF
Patritumab[43]		mab	human	ERBB3 (HER3)		cancer
PDR001			humanized	PD-1		melanoma
Pembrolizumab[52]	Keytruda	mab	humanized	PD-1	Y[98]	melanoma and other cancers
Pemtumomab	Theragyn		mouse	MUC1		cancer
Perakizumab[15]		mab	humanized	IL-17A		arthritis
Pertuzumab	Perjeta	mab	humanized	HER2/neu	Y	cancer
Pexelizumab[17]		scFv	humanized	C5		reduction of side effects of cardiac surgery
Pidilizumab[39]		mab	humanized	PD-1		cancer and infectious diseases
Pinatuzumab vedotin[39]		mab	humanized	CD22		cancer
Pintumomab		mab	mouse	adenocarcinoma antigen		adenocarcinoma (imaging)
Placulumab[15]		mab	human	TNF		pain and inflammatory diseases
Pozelimab[34]	Veopoz	mab	human	C5	Y	CHAPLE disease
Prezalumab[40]		mab	human	TNF
Plozalizumab[12]		mab	humanized	CCR2		diabetic nephropathy and arteriovenous graft patency
Pogalizumab[40]		mab	humanized	tumor necrosis factor receptor (TNFR) superfamily member 4
Polatuzumab vedotin[50][4]	Polivy	mab	humanized	CD79B	Y	diffuse large B-cell lymphoma
Ponezumab		mab	humanized	β-amyloid		Alzheimer's disease
Porgaviximab[27]		mab	chimeric	Zaire ebolavirus glycoprotein		Ebola virus disease
Prasinezumab[26]		mab	humanized	Alpha-synuclein		Parkinson's disease
Prezalizumab[40]		mab	humanized	inducible T-cell co-stimulatory ligand (ICOSL)
Priliximab		mab	chimeric	CD4		Crohn's disease, multiple sclerosis
Pritoxaximab[39]		mab	chimeric	E. coli shiga toxin type-1
Pritumumab		mab	human	vimentin		brain cancer
PRO 140			humanized	CCR5		HIV infection
Quilizumab[43]		mab	humanized	IGHE		asthma
Racotumomab[93]	Vaxira	mab	mouse	NGNA ganglioside	Y	non-small cell lung cancer
Radretumab[16]		mab	human	fibronectin extra domain-B		cancer
Rafivirumab[48]		mab	human	rabies virus glycoprotein		rabies (prophylaxis)
Ralpancizumab		mab	humanized	PCSK9		dyslipidemia
Ramucirumab	Cyramza	mab	human	VEGFR2	Y	solid tumors
Ranevetmab		mab	veterinary	NGF		osteoarthritis in dogs
Ranibizumab[9]	Lucentis	Fab	humanized	VEGF-A	Y	macular degeneration (wet form)
Raxibacumab[38]		mab	human	anthrax toxin, protective antigen	Y	anthrax (prophylaxis and treatment)
Ravagalimab[5]		mab	humanized	CD40		Crohn's disease
Ravulizumab[26]	Ultomiris	mab	humanized	C5	Y	paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Refanezumab		mab	humanized	myelin-associated glycoprotein		recovery of motor function after stroke
Regavirumab		mab	human	cytomegalovirus glycoprotein B		cytomegalovirus infection
Regdanvimab[28]	Regkirona[99]	mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Y[99]	COVID-19
Relatlimab		mab	human	LAG3		melanoma
Remtolumab[22]		mab	human	IL-17A, TNF
Reslizumab[7]	Cinqair	mab	humanized	IL-5	Y	inflammations of the airways, skin and gastrointestinal tract
Retifanlimab[60]	Zynyz[100]	mab	humanized	PD-1	Y	Merkel cell carcinoma
Rilotumumab		mab	human	hepatocyte growth factor (HGF)		solid tumors
Rinucumab		mab	human	PDGFRB		neovascular age-related macular degeneration
Risankizumab[12]	Skyrizi	mab	humanized	IL-23A	Y	Crohn's disease, psoriasis, psoriatic arthritis, and asthma
Rituximab	MabThera, Rituxan	mab	chimeric	CD20	Y[101]	lymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol[12]		mab	humanized	Pseudomonas aeruginosa type III secretion system
Robatumumab		mab	human	IGF-1 receptor (CD221)		cancer
Rmab	RabiShield		human	rabies virus G glycoprotein	Y	post-exposure prophylaxis of rabies
Roledumab[72]		mab	human	RHD (gene) (RHD)		Rh disease
Romilkimab[5]		mab	chimeric/ humanized	IL-13
Romosozumab	Evenity	mab	humanized	sclerostin	Y	osteoporosis
Rontalizumab[53]		mab	humanized	IFN-α		systemic lupus erythematosus
Rosmantuzumab[22]		mab	humanized	root plate-specific spondin 3		cancer
Rovalpituzumab tesirine[12]		mab	humanized	DLL3		small cell lung cancer
Rovelizumab[46]	LeukArrest	mab	humanized	CD11, CD18	Y	haemorrhagic shock etc.
Rozanolixizumab[22]	Rystiggo	mab	chimeric/ humanized	FCGRT	Y[102]	myasthenia gravis
Ruplizumab[14]	Antova	mab	humanized	CD154 (CD40L)	Y	rheumatic diseases
SA237			humanized	IL-6 receptor		neuromyelitis optica and neuromyelitis optica spectrum disorders
Sacituzumab govitecan[22]	Trodelvy	mab	humanized	TROP-2	Y[103]	triple-negative breast cancer
Samalizumab[41]		mab	humanized	CD200		cancer
Samrotamab vedotin[5]		mab	chimeric/ humanized	LRRC15		cancer
Sarilumab[43]	Kevzara	mab	human	IL-6	Y	rheumatoid arthritis, ankylosing spondylitis
Satralizumab[73]	Enspryng	mab	humanized	IL-6 receptor	Y	neuromyelitis optica
Satumomab pendetide		mab	mouse	TAG-72		cancer (diagnosis)
Secukinumab	Cosentyx	mab	human	IL-17A	Y	uveitis, rheumatoid arthritis psoriasis
Selicrelumab[27]		mab	human	CD40
Seribantumab[39]		mab	human	ERBB3 (HER3)		cancer
Setoxaximab[39]		mab	chimeric	E. coli shiga toxin type-2
Setrusumab[26]		mab	human	sclerostin (SOST)
Sevirumab			human	cytomegalovirus		cytomegalovirus infection
Sibrotuzumab		mab	humanized	FAP (gene) (FAP)		cancer
SGN-CD19A		mab	humanized	CD19		acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SHP647			human	mucosal addressin cell adhesion molecule		Crohn's disease
Sifalimumab[16]		mab	human	IFN-α		systemic lupus erythematosus (SLE), dermatomyositis, polymyositis
Siltuximab	Sylvant	mab	chimeric	IL-6	Y	cancer
Simtuzumab[15]		mab	humanized	LOXL2		fibrosis
Siplizumab[21]		mab	humanized	CD2		psoriasis, graft-versus-host disease (prevention)
Sirtratumab vedotin[26]		mab	human	SLITRK6		cancer
Sirukumab		mab	human	IL-6		rheumatoid arthritis
Sofituzumab vedotin		mab	humanized	CA-125		ovarian cancer
Solanezumab[93]		mab	humanized	β-amyloid		Alzheimer's disease
Solitomab[43]		BiTE	mouse	EpCAM		gastrointestinal, lung, and other cancers
Sonepcizumab[104]			humanized	sphingosine-1-phosphate		choroidal and retinal neovascularization
Sontuzumab[95]		mab	humanized	episialin
Sotrovimab[28]	Xevudy	mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Y[105][106]	COVID-19
Spartalizumab[26]		mab	humanized	PD-1		melanoma
Spesolimab[107]	Spevigo	mab	humanized	Interleukin 36 receptor (IL1RL2/IL1RAP)	Y	generalized pustular psoriasis (GPP)
Stamulumab[96]		mab	human	myostatin		muscular dystrophy
Sulesomab	LeukoScan	Fab'	mouse	NCA-90 (granulocyte antigen)		osteomyelitis (imaging)
Suptavumab[22]		mab	human	RSVFR		medically attended lower respiratory disease
Sutimlimab[66]	Enjaymo	mab	chimeric/ humanized	complement component 1s (C1s)	Y	cold agglutinin disease
Suvizumab[37]		mab	humanized	HIV-1		viral infections
Suvratoxumab[27]		mab	human	Staphylococcus aureus alpha toxin		nosocomial pneumonia
Tabalumab[41]		mab	human	B-cell activating factor (BAFF)		B-cell cancers
Tacatuzumab tetraxetan	AFP-Cide	mab	humanized	alpha-fetoprotein		cancer
Tadocizumab[95]		Fab	humanized	integrin α_IIbβ₃		percutaneous coronary intervention
Tafasitamab[46]	Monjuvi	mab	humanized (from mouse)	CD19	Y	relapsed or refractory diffuse large B-cell lymphoma
Talacotuzumab[26]		mab	humanized	CD123		leukemia etc.
Talizumab[36]		mab	humanized	IgE		allergic reaction
Talquetamab	Talvey	BsAb	humanized	GPRC5D, CD3	Y	relapsed or refractory multiple myeloma
Tamtuvetmab[40]	Tactress	mab	veterinary	CD52
Tanezumab[48]		mab	humanized	nerve growth factor (NGF)		pain
Taplitumomab paptox[64]		mab	mouse	CD19		cancer
Tarextumab		mab	human	Notch receptor		cancer
Tavolimab		mab	chimeric/ humanized	CD134		cancer
Teclistamab	Tecvayli[34]	BsAb	human	B-cell maturation antigen (BCMA), CD3	Y[108][109]	relapsed or refractory multiple myeloma
Tefibazumab[38]	Aurexis	mab	humanized	clumping factor A		Staphylococcus aureus infection
Telimomab aritox		Fab	mouse
Telisotuzumab[22]		mab	humanized	HGFR		cancer
Telisotuzumab vedotin[22]		mab	humanized	HGFR		cancer
Tenatumomab[13]		mab	mouse	tenascin C		cancer
Teneliximab[21]		mab	chimeric	CD40		autoimmune diseases and prevention of organ transplant rejection
Teplizumab[42]	Tzield	mab	humanized	CD3	Y	diabetes mellitus type 1
Tepoditamab[5]		mab	human	dendritic cell-associated lectin 2		cancer
Teprotumumab	Tepezza	mab	human	IGF-1 receptor (CD221)	Y	thyroid eye disease
Tesidolumab[25]		mab	human	C5
Tetulomab		mab	humanized	CD37		cancer[110]
Tezepelumab[12]	Tezspire	mab	human	thymic stromal lymphopoietin (TSLP)	Y[111]	asthma
TGN1412			humanized	CD28		chronic lymphocytic leukemia, rheumatoid arthritis
Tibulizumab[26]		mab	humanized	B-cell activating factor (BAFF)		autoimmune disorders
Tildrakizumab	Ilumya	mab	humanized	IL-23	Y	immunologically mediated inflammatory disorders
Tigatuzumab[13]		mab	humanized	TRAIL-R2		cancer
Timigutuzumab[27]		mab	humanized	HER2		cancer
Timolumab[40]		mab	human	AOC3
tiragolumab[26]		mab	human
Tiragotumab[26]		mab	human	TIGIT		cancer
Tislelizumab[26]		mab	humanized	PCDC1, CD279		non-small cell lung cancer
Tisotumab vedotin[12]	Tivdak	mab	human	coagulation factor III	Y	relapsed or refractory cervical cancer[112][113]
Tixagevimab[28]		mab	human	spike protein receptor binding domain (RBD) of SARS-CoV-2	Emergency Use Authorization (EUA) when used with cilgavimab[47]	COVID-19
TNX-650			humanized	IL-13		Hodgkin's lymphoma
Tocilizumab[9]	Actemra, RoActemra	mab	humanized	IL-6 receptor	Y[114]	rheumatoid arthritis
Tomuzotuximab[27]		mab	humanized	Epidermal growth factor receptor (EGFR), HER1		cancer
Toralizumab[21]		mab	humanized	CD154 (CD40L)		rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[4]		mab	human	Staphylococcus aureus
Tositumomab	Bexxar		mouse	CD20	Y	follicular lymphoma
Tovetumab		mab	human	PDGFRA		cancer
Tralokinumab[115]	Adtralza, Adbry[116]	mab	human	IL-13	Y[116]	atopic dermatitis
Trastuzumab	Herceptin	mab	humanized	HER2/neu	Y	breast cancer
Trastuzumab duocarmazine[22]	Kadcyla	mab	humanized	HER2/neu	Y	breast cancer
Trastuzumab emtansine	Kadcyla	mab	humanized	HER2/neu	Y	breast cancer
TRBS07[117]	Ektomab	3funct		GD2 ganglioside		melanoma
Tregalizumab[16]		mab	humanized	CD4
Tremelimumab[118]	Imjudo	mab	human	CTLA-4	Y[119]	hepatocellular carcinoma
Trevogrumab		mab	human	growth differentiation factor 8		muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[55][95]		mab	humanized	EpCAM		cancer
Tuvirumab			human	hepatitis B virus		chronic hepatitis B
Ublituximab[120]	Briumvi	mab	chimeric	CD20	Y	multiple sclerosis, chronic lymphocytic leukemia
Ulocuplumab[52]		mab	human	CXCR4 (CD184)		hematologic malignancies
Urelumab[16]		mab	human	4-1BB (CD137)		cancer etc.
Urtoxazumab[9]		mab	humanized	Escherichia coli		diarrhoea caused by E. coli
Ustekinumab[48]	Stelara	mab	human	IL-12, IL-23	Y	multiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab[22]		mab	human	4-1BB (CD137)		diffuse large B-cell lymphoma
Vadastuximab talirine[12]		mab	chimeric	CD33		Acute myeloid leukemia
Vanalimab[5]		mab	humanized	CD40
Vandortuzumab vedotin[25]		mab	humanized	STEAP1		cancer
Vantictumab		mab	human	Frizzled receptor		cancer
Vanucizumab[6]		mab	humanized	angiopoietin 2		cancer
Vapaliximab[21]		mab	chimeric	AOC3 (VAP-1)
Varisacumab[27]		mab	human	VEGF-A		angiogenesis
Varlilumab[6]		mab	human	CD27		solid tumors and hematologic malignancies
Vatelizumab[41]		mab	humanized	ITGA2 (CD49b)
Vedolizumab[93]	Entyvio	mab	humanized	integrin α₄ β₇	Y[121]	Crohn's disease, ulcerative colitis
Veltuzumab[13]		mab	humanized	CD20		non-Hodgkin's lymphoma
Vepalimomab		mab	mouse	AOC3 (VAP-1)		inflammation
Vesencumab[16]		mab	human	NRP1		solid malignancies
Vilobelimab[82]	Gohibic	mab	chimeric	C5a receptor (C5a)	Emergency Use Authorization (EUA)[122]	COVID-19
Visilizumab[64]	Nuvion	mab	humanized	CD3		Crohn's disease, ulcerative colitis
Vobarilizumab[40]		scFv	humanized	IL-6 receptor		inflammatory autoimmune diseases
Volociximab[30]		mab	chimeric	integrin α₅β₁		solid tumors
Vonlerolizumab[27]		mab	humanized	CD134		cancer
Vopratelimab[5]		mab	humanized	CD278, aka ICOS
Vorsetuzumab mafodotin		mab	humanized	CD70		cancer
Votumumab	HumaSPECT	mab	human	tumor antigen CTAA16.88		colorectal tumors
Vunakizumab[22]		mab	humanized	IL-17A
Xentuzumab[40]		mab	humanized	IGF-1, IGF-2		?
XMAB-5574			humanized	CD19		diffuse large B-cell lymphoma
Zalutumumab[30]		mab	human	Epidermal growth factor receptor (EGFR)		squamous cell carcinoma of the head and neck
Zanolimumab[38]		mab	human	CD4		rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[15]		mab	chimeric	HER1		cancer
Zenocutuzumab[26]		mab	humanized	ERBB3 (HER3)		cancer
Ziralimumab[64]		mab	human	CD147 (basigin)
Zolbetuximab[26]		mab	chimeric	Claudin 18 Isoform 2		gastric cancer, gastrointestinal adenocarcinoma and pancreatic cancer
Zolimomab aritox		mab	mouse	CD5		systemic lupus erythematosus, graft-versus-host disease

References

World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 57". WHO Drug Information. 21 (1). hdl:10665/74004.
World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 80" (PDF). WHO Drug Information. 12 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
"ReoPro Abciximab". DailyMed. 4 May 2020. Archived from the original on 6 September 2022. Retrieved 28 June 2022.
World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1). hdl:10665/331151.
World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 118" (PDF). WHO Drug Information. 31 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 111" (PDF). WHO Drug Information. 28 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
World Health Organization (2001). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 85" (PDF). WHO Drug Information. 15 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
"Humira- adalimumab kit Humira- adalimumab injection, solution". DailyMed. Archived from the original on 21 June 2020. Retrieved 18 February 2020.
World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 90" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.
"Aduhelm- aducanumab injection, solution". DailyMed. Archived from the original on 14 June 2021. Retrieved 14 June 2021.
World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.
World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 98" (PDF). WHO Drug Information. 21 (4). Archived (PDF) from the original on 3 March 2016. Retrieved 5 October 2020.
World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 83" (PDF). WHO Drug Information. 14 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 107" (PDF). WHO Drug Information. 26 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 86" (PDF). WHO Drug Information. 16 (1). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 115" (PDF). WHO Drug Information. 30 (2). Archived (PDF) from the original on 5 February 2018. Retrieved 5 October 2020.
"Saphnelo- anifrolumab injection, solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.
"Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on 12 June 2008. Retrieved 19 November 2008.
World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 87" (PDF). WHO Drug Information. 16 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.
World Health Organization (1995). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 74" (PDF). WHO Drug Information. 9 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 24 January 2020.
World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 88" (PDF). WHO Drug Information. 17 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 112" (PDF). WHO Drug Information. 28 (4). Archived (PDF) from the original on 28 August 2021. Retrieved 5 October 2020.
World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 117" (PDF). WHO Drug Information. 31 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 116" (PDF). WHO Drug Information. 30 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.
"Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 18 March 2021. Retrieved 18 March 2021.
World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 93" (PDF). WHO Drug Information. 19 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2019). International Nonproprietary Names (INN) for biological and biotechnological substances (PDF). World Health Organization (WHO). WHO/EMP/RHT/TSN/2019.1. Archived (PDF) from the original on 19 January 2022. Retrieved 22 January 2020.
World Health Organization (2021). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 126 – COVID-19 (special edition)". WHO Drug Information. 35 (4): 1130–1. Archived from the original on 13 February 2022. Retrieved 13 February 2022.
"Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bebtelovimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 11 February 2022. Retrieved 12 February 2022.
World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
"Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 – via Business Wire.
World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 89" (PDF). WHO Drug Information. 17 (3).
World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 102" (PDF). WHO Drug Information. 23 (4). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 92" (PDF). WHO Drug Information. 18 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 108" (PDF). WHO Drug Information. 26 (4). Archived (PDF) from the original on 4 March 2016. Retrieved 5 October 2020.
World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 114" (PDF). WHO Drug Information. 29 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 105" (PDF). WHO Drug Information. 25 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 97" (PDF). WHO Drug Information. 21 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 106" (PDF). WHO Drug Information. 25 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
"Ronapreve EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 13 November 2021. Retrieved 12 November 2021.
"Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. Archived from the original on 24 July 2021. Retrieved 29 August 2021.
World Health Organization (1999). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 81" (PDF). WHO Drug Information. 13 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
"Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals". U.S. Food and Drug Administration (FDA) (Press release). 8 December 2021. Archived from the original on 28 April 2022. Retrieved 9 December 2021. This article incorporates text from this source, which is in the public domain.
World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 99" (PDF). WHO Drug Information. 22 (2). Archived (PDF) from the original on 25 October 2021. Retrieved 5 October 2020.
"BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. Archived from the original on 13 November 2009. Retrieved 11 November 2009.
World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 78" (PDF). WHO Drug Information. 11 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 110" (PDF). WHO Drug Information. 27 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 101" (PDF). WHO Drug Information. 23 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
"Darzalex- daratumumab injection, solution, concentrate Darzalex IV- daratumumab injection, solution, concentrate". DailyMed. Archived from the original on 19 December 2021. Retrieved 18 December 2021.
World Health Organization (2005). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 94" (PDF). WHO Drug Information. 19 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (1991). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 66" (PDF). WHO Drug Information. 5 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 119" (PDF). WHO Drug Information. 32 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 5 October 2020.
"Padcev ejfv- enfortumab vedotin injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 11 December 2021. Retrieved 18 December 2021.
World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 77" (PDF). WHO Drug Information. 11 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.
World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 51" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
"Vyepti- eptinezumab-jjmr injection". DailyMed. Archived from the original on 28 September 2021. Retrieved 27 September 2021.
World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 84" (PDF). WHO Drug Information. 14 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 91" (PDF). WHO Drug Information. 18 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.
Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160. S2CID 29327089.
Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 113" (PDF). WHO Drug Information. 29 (2). Archived (PDF) from the original on 4 November 2021. Retrieved 5 October 2020.
World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 103" (PDF). WHO Drug Information. Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
"FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022. This article incorporates text from this source, which is in the public domain.
"Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®" (Press release). Archived from the original on 7 July 2017. Retrieved 2 May 2011.
NCI Drug Dictionary: Glemtumumab vedotin Archived 5 April 2015 at the Wayback Machine
"FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma" (Press release). F. Hoffmann-La Roche Ltd. 16 June 2023. Retrieved 16 June 2023 – via GlobeNewswire.
"Results from Cure Brain Cancer Foundation-funded trial show promise". www.curebraincancer.org.au. Archived from the original on 19 March 2020. Retrieved 14 June 2019.
"Uplizna- inebilizumab injection". DailyMed. 8 July 2019. Archived from the original on 13 June 2020. Retrieved 13 June 2020.
Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.
"FDA Grants Accelerated Approval for Alzheimer's Disease Treatment". U.S. Food and Drug Administration (FDA) (Press release). 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023.
World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.
Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Archived from the original on 7 July 2018. Retrieved 6 July 2018.
"Margenza: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 March 2021. Retrieved 17 December 2020.
"FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer". U.S. Food and Drug Administration (FDA). 14 November 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.
World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 79" (PDF). WHO Drug Information. 12 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
"FDA grants accelerated approval to mosunetuzumab-axgb". U.S. Food and Drug Administration. 22 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023.
Wilde, Michelle I.; Goa, Karen L. (1 May 1996). "Muromonab CD3". Drugs. 51 (5): 865–894. doi:10.2165/00003495-199651050-00010. ISSN 1179-1950. PMID 8861551. S2CID 13220985.
Hooks, M. A.; Wade, C. S.; Millikan, W. J. (1991). "Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation". Pharmacotherapy. 11 (1): 26–37. ISSN 0277-0008. PMID 1902291. Archived from the original on 10 September 2021. Retrieved 10 September 2021.
World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 96" (PDF). WHO Drug Information. 20 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 100 (prepublication copy)" (PDF). WHO Drug Information. Archived (PDF) from the original on 29 August 2021. Retrieved 5 October 2020.
Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jonathan; Kabashima, Kenji; XCIMA Study Group (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.
World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 56" (PDF). WHO Drug Information. 20 (3). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 95" (PDF). WHO Drug Information. 20 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
"FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis" (Press release). Novartis. 20 August 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
"Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Archived from the original on 17 June 2020. Retrieved 10 January 2020.
"Regkirona EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021.
"ZYNYZ™ (retifanlimab-dlwr) injection, for intravenous use" (PDF). Archived (PDF) from the original on 23 March 2023. Retrieved 23 March 2023.
"Rituxan- rituximab injection, solution". DailyMed. 6 November 2019. Archived from the original on 4 August 2020. Retrieved 2 February 2020.
"UCB announces U.S. FDA approval of Rystiggo (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis" (Press release). UCB. 27 June 2023. Retrieved 28 June 2023 – via PR Newswire.
"Trodelvy- sacituzumab govitecan powder, for solution". DailyMed. Archived from the original on 20 March 2021. Retrieved 9 April 2021.
Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.
"AusPAR: Sotrovimab". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 1 November 2021. Retrieved 4 September 2021.
"Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
"Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma". Janssen Pharmaceutical Companies (Press release). 24 August 2022. Archived from the original on 26 October 2022. Retrieved 26 October 2022.
"U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma". Janssen Pharmaceutical Companies. 25 October 2022. Retrieved 26 October 2022.
Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research. 33 (1): 85–95. PMID 23267131.
"Tezspire- tezepelumab-ekko injection, solution". DailyMed. 17 December 2021. Archived from the original on 25 December 2021. Retrieved 28 June 2022.
Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Archived from the original on 23 February 2018. Retrieved 22 February 2018.
"Enforcement Reports" (PDF). Archived (PDF) from the original on 21 September 2021. Retrieved 21 September 2021.
"RoActemra EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 18 December 2021. Retrieved 18 December 2021.
World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 64". WHO Drug Information. 24 (3). hdl:10665/74577.
"LEO Pharma announces FDA approval of Adbry tralokinumab". LEO Pharma (Press release). Archived from the original on 28 December 2021. Retrieved 28 December 2021.
Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099. S2CID 25197165.
World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 59". WHO Drug Information. 22 (1). hdl:10665/74120.
"Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer". AstraZeneca (Press release). 26 October 2022. Archived from the original on 24 October 2022. Retrieved 26 October 2022.
World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). hdl:10665/74683.
"Entyvio- vedolizumab injection, powder, lyophilized, for solution". DailyMed. 3 April 2020. Archived from the original on 21 October 2020. Retrieved 12 October 2020.
"FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 4 April 2023. Retrieved 4 April 2023.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[WHORecList57-1] World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 57". WHO Drug Information. 21 (1). hdl:10665/74004.

[WHOList80-2] World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 80" (PDF). WHO Drug Information. 12 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[3] "ReoPro Abciximab". DailyMed. 4 May 2020. Archived from the original on 6 September 2022. Retrieved 28 June 2022.

[WHORecList71-4] World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1). hdl:10665/331151.

[WHOList118-5] World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 118" (PDF). WHO Drug Information. 31 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.

[WHOList111-6] World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 111" (PDF). WHO Drug Information. 28 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.

[WHOList85-7] World Health Organization (2001). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 85" (PDF). WHO Drug Information. 15 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[8] "Humira- adalimumab kit Humira- adalimumab injection, solution". DailyMed. Archived from the original on 21 June 2020. Retrieved 18 February 2020.

[WHOList90-9] World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 90" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.

[WHORecList72-10] World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.

[11] "Aduhelm- aducanumab injection, solution". DailyMed. Archived from the original on 14 June 2021. Retrieved 14 June 2021.

[WHORecList75-12] World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.

[WHOList98-13] World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 98" (PDF). WHO Drug Information. 21 (4). Archived (PDF) from the original on 3 March 2016. Retrieved 5 October 2020.

[WHOList83-14] World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 83" (PDF). WHO Drug Information. 14 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.

[WHOList107-15] World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 107" (PDF). WHO Drug Information. 26 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.

[WHOList104-16] World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList86-17] World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 86" (PDF). WHO Drug Information. 16 (1). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.

[WHOList115-18] World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 115" (PDF). WHO Drug Information. 30 (2). Archived (PDF) from the original on 5 February 2018. Retrieved 5 October 2020.

[Saphnelo_FDA_label-19] "Saphnelo- anifrolumab injection, solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.

[IMA-638-20] "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on 12 June 2008. Retrieved 19 November 2008.

[WHOList87-21] World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 87" (PDF). WHO Drug Information. 16 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.

[WHORecList77-22] World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.

[WHOList74-23] World Health Organization (1995). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 74" (PDF). WHO Drug Information. 9 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 24 January 2020.

[WHOList88-24] World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 88" (PDF). WHO Drug Information. 17 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList112-25] World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 112" (PDF). WHO Drug Information. 28 (4). Archived (PDF) from the original on 28 August 2021. Retrieved 5 October 2020.

[WHOList117-26] World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 117" (PDF). WHO Drug Information. 31 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.

[WHOList116-27] World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 116" (PDF). WHO Drug Information. 30 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.

[WHORecList85-28] World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.

[FDA_Fact_Sheet_Bamlanivimab/Etesevimab-29] "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 18 March 2021. Retrieved 18 March 2021.

[WHOList93-30] World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 93" (PDF). WHO Drug Information. 19 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHO_BioReview2019-31] World Health Organization (2019). International Nonproprietary Names (INN) for biological and biotechnological substances (PDF). World Health Organization (WHO). WHO/EMP/RHT/TSN/2019.1. Archived (PDF) from the original on 19 January 2022. Retrieved 22 January 2020.

[WHO_Drug_v35n4-32] World Health Organization (2021). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 126 – COVID-19 (special edition)". WHO Drug Information. 35 (4): 1130–1. Archived from the original on 13 February 2022. Retrieved 13 February 2022.

[FDA_Fact_Sheet_Bebtelovimab-33] "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bebtelovimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 11 February 2022. Retrieved 12 February 2022.

[WHORecList82-34] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

[Zoetis_PR-35] "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 – via Business Wire.

[WHOList89-36] World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 89" (PDF). WHO Drug Information. 17 (3).

[WHOList102-37] World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 102" (PDF). WHO Drug Information. 23 (4). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.

[WHOList92-38] World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 92" (PDF). WHO Drug Information. 18 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList108-39] World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 108" (PDF). WHO Drug Information. 26 (4). Archived (PDF) from the original on 4 March 2016. Retrieved 5 October 2020.

[WHOList114-40] World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 114" (PDF). WHO Drug Information. 29 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.

[WHOList105-41] World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 105" (PDF). WHO Drug Information. 25 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.

[WHOList97-42] World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 97" (PDF). WHO Drug Information. 21 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList106-43] World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 106" (PDF). WHO Drug Information. 25 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.

[Ronapreve_EPAR-44] "Ronapreve EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 13 November 2021. Retrieved 12 November 2021.

[Roche_PR_20210720-45] "Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. Archived from the original on 24 July 2021. Retrieved 29 August 2021.

[WHOList81-46] World Health Organization (1999). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 81" (PDF). WHO Drug Information. 13 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[FDA_PR_20211208-47] "Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals". U.S. Food and Drug Administration (FDA) (Press release). 8 December 2021. Archived from the original on 28 April 2022. Retrieved 9 December 2021. This article incorporates text from this source, which is in the public domain.

[WHOList99-48] World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 99" (PDF). WHO Drug Information. 22 (2). Archived (PDF) from the original on 25 October 2021. Retrieved 5 October 2020.

[ALD518-49] "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. Archived from the original on 13 November 2009. Retrieved 11 November 2009.

[WHORecList70-50] World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.

[WHOList78-51] World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 78" (PDF). WHO Drug Information. 11 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.

[WHOList110-52] World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 110" (PDF). WHO Drug Information. 27 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.

[WHOList101-53] World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 101" (PDF). WHO Drug Information. 23 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.

[Darzalex_FDA_label-54] "Darzalex- daratumumab injection, solution, concentrate Darzalex IV- daratumumab injection, solution, concentrate". DailyMed. Archived from the original on 19 December 2021. Retrieved 18 December 2021.

[WHOList94-55] World Health Organization (2005). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 94" (PDF). WHO Drug Information. 19 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList66-56] World Health Organization (1991). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 66" (PDF). WHO Drug Information. 5 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.

[WHOList119-57] World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 119" (PDF). WHO Drug Information. 32 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 5 October 2020.

[58] "Padcev ejfv- enfortumab vedotin injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 11 December 2021. Retrieved 18 December 2021.

[WHOList77-59] World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 77" (PDF). WHO Drug Information. 11 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.

[WHORecList83-60] World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

[WHORecList88-61] World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.

[WHOList51-62] World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 51" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[Vyepti_FDA_label-63] "Vyepti- eptinezumab-jjmr injection". DailyMed. Archived from the original on 28 September 2021. Retrieved 27 September 2021.

[WHOList84-64] World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 84" (PDF). WHO Drug Information. 14 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList91-65] World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 91" (PDF). WHO Drug Information. 18 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHORecList80-66] World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.

[67] Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.

[68] Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160. S2CID 29327089.

[NCT00883896-69] Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov

[NCT00563524-70] Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov

[WHOList113-71] World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 113" (PDF). WHO Drug Information. 29 (2). Archived (PDF) from the original on 4 November 2021. Retrieved 5 October 2020.

[WHOList103-72] World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 103" (PDF). WHO Drug Information. Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHORecList78-73] World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.

[FDA_PR_20220113-74] "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022. This article incorporates text from this source, which is in the public domain.

[75] "Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®" (Press release). Archived from the original on 7 July 2017. Retrieved 2 May 2011.

[Glembatumumab-76] NCI Drug Dictionary: Glemtumumab vedotin Archived 5 April 2015 at the Wayback Machine

[Roche_PR_20230616-77] "FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma" (Press release). F. Hoffmann-La Roche Ltd. 16 June 2023. Retrieved 16 June 2023 – via GlobeNewswire.

[78] "Results from Cure Brain Cancer Foundation-funded trial show promise". www.curebraincancer.org.au. Archived from the original on 19 March 2020. Retrieved 14 June 2019.

[Uplizna_FDA_label-79] "Uplizna- inebilizumab injection". DailyMed. 8 July 2019. Archived from the original on 13 June 2020. Retrieved 13 June 2020.

[NCT00537381-80] Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov

[NCT00246012-81] Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov

[WHORecList84-82] World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.

[FDA_PR_20230106-83] "FDA Grants Accelerated Approval for Alzheimer's Disease Treatment". U.S. Food and Drug Administration (FDA) (Press release). 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023.

[WHORecList79-84] World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.

[Guthrie_2017-85] Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Archived from the original on 7 July 2018. Retrieved 6 July 2018.

[86] "Margenza: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 March 2021. Retrieved 17 December 2020.

[87] "FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer". U.S. Food and Drug Administration (FDA). 14 November 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.

[WHOList79-88] World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 79" (PDF). WHO Drug Information. 12 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[89] "FDA grants accelerated approval to mosunetuzumab-axgb". U.S. Food and Drug Administration. 22 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023.

[90] Wilde, Michelle I.; Goa, Karen L. (1 May 1996). "Muromonab CD3". Drugs. 51 (5): 865–894. doi:10.2165/00003495-199651050-00010. ISSN 1179-1950. PMID 8861551. S2CID 13220985.

[91] Hooks, M. A.; Wade, C. S.; Millikan, W. J. (1991). "Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation". Pharmacotherapy. 11 (1): 26–37. ISSN 0277-0008. PMID 1902291. Archived from the original on 10 September 2021. Retrieved 10 September 2021.

[WHOList96-92] World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 96" (PDF). WHO Drug Information. 20 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList100-93] World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 100 (prepublication copy)" (PDF). WHO Drug Information. Archived (PDF) from the original on 29 August 2021. Retrieved 5 October 2020.

[94] Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jonathan; Kabashima, Kenji; XCIMA Study Group (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.

[WHOList56-95] World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 56" (PDF). WHO Drug Information. 20 (3). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[WHOList95-96] World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 95" (PDF). WHO Drug Information. 20 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.

[Novartis_PR-97] "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis" (Press release). Novartis. 20 August 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.

[Keytruda_label-98] "Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Archived from the original on 17 June 2020. Retrieved 10 January 2020.

[Regkirona_EPAR-99] "Regkirona EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021.

[Zynyz_FDA_label-100] "ZYNYZ™ (retifanlimab-dlwr) injection, for intravenous use" (PDF). Archived (PDF) from the original on 23 March 2023. Retrieved 23 March 2023.

[Rituxan_FDA_label-101] "Rituxan- rituximab injection, solution". DailyMed. 6 November 2019. Archived from the original on 4 August 2020. Retrieved 2 February 2020.

[102] "UCB announces U.S. FDA approval of Rystiggo (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis" (Press release). UCB. 27 June 2023. Retrieved 28 June 2023 – via PR Newswire.

[Trodelvy_FDA_label-103] "Trodelvy- sacituzumab govitecan powder, for solution". DailyMed. Archived from the original on 20 March 2021. Retrieved 9 April 2021.

[104] Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.

[AusPAR:_Sotrovimab-105] "AusPAR: Sotrovimab". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 1 November 2021. Retrieved 4 September 2021.

[Xevudy_EPAR-106] "Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.

[WHORecList81-107] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

[108] "Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma". Janssen Pharmaceutical Companies (Press release). 24 August 2022. Archived from the original on 26 October 2022. Retrieved 26 October 2022.

[109] "U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma". Janssen Pharmaceutical Companies. 25 October 2022. Retrieved 26 October 2022.

[110] Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research. 33 (1): 85–95. PMID 23267131.

[Tezspire_FDA_label-111] "Tezspire- tezepelumab-ekko injection, solution". DailyMed. 17 December 2021. Archived from the original on 25 December 2021. Retrieved 28 June 2022.

[112] Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Archived from the original on 23 February 2018. Retrieved 22 February 2018.

[Tivdak_FDA_label-113] "Enforcement Reports" (PDF). Archived (PDF) from the original on 21 September 2021. Retrieved 21 September 2021.

[RoActemra_EPAR-114] "RoActemra EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 18 December 2021. Retrieved 18 December 2021.

[WHORecList64-115] World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 64". WHO Drug Information. 24 (3). hdl:10665/74577.

[LEO_Pharma_PR-116] "LEO Pharma announces FDA approval of Adbry tralokinumab". LEO Pharma (Press release). Archived from the original on 28 December 2021. Retrieved 28 December 2021.

[117] Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099. S2CID 25197165.

[WHORecList59-118] World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 59". WHO Drug Information. 22 (1). hdl:10665/74120.

[119] "Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer". AstraZeneca (Press release). 26 October 2022. Archived from the original on 24 October 2022. Retrieved 26 October 2022.

[WHORecList66-120] World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). hdl:10665/74683.

[Entyvio_FDA_label-121] "Entyvio- vedolizumab injection, powder, lyophilized, for solution". DailyMed. 3 April 2020. Archived from the original on 21 October 2020. Retrieved 12 October 2020.

[122] "FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 4 April 2023. Retrieved 4 April 2023.

Engineered monoclonal antibodies and antibody mimetics
Whole antibody	bispecific: Trifunctional antibody
Fab fragment	F(ab')₂ fragment / Fab' fragment bispecific: Chemically linked Fab
Variable fragment	Single-chain variable fragment / di-scFv / tri-scFv Single-domain antibody Small modular immunopharmaceutical bispecific: T-cell engager
Smaller units	Microantibody
Intracellular	Intrabody
Antibody mimetics	Affibody molecule Affilin Affimer Affitin Alphabody Anticalin Avimer DARPin Kunitz domain peptide Monobody nanoCLAMP